UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Milestone for CAR T Cells

The New England journal of medicine, 2017-12, Vol.377 (26), p.2593-2596

2017

Volltextzugriff (PDF)

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5542-5551

2005

Volltextzugriff (PDF)

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Volltextzugriff (PDF)

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3133-3140

2003

Volltextzugriff (PDF)

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

The Journal of immunology (1950), 2000-02, Vol.164 (4), p.2160-2169

2000

Volltextzugriff (PDF)

Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-09-12

2019

Volltextzugriff (PDF)

Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-09-03

2019

Volltextzugriff (PDF)

Development of antitumor immune responses in reconstituted lymphopenic hosts

Cancer research (Chicago, Ill.), 2002-07, Vol.62 (14), p.3914-3919

2002

Volltextzugriff (PDF)

Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing

Cancer research (Chicago, Ill.), 2005-11, Vol.65 (22), p.10569-10577

2005

Volltextzugriff (PDF)

Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution

European journal of immunology, 2003-08, Vol.33 (8), p.2123-2132

2003

Volltextzugriff (PDF)

Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1562-1573

2003

Volltextzugriff (PDF)

Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy

The Journal of immunology (1950), 2000-10, Vol.165 (8), p.4246-4253

2000

Volltextzugriff (PDF)

Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile

The Journal of immunology (1950), 1998-09, Vol.161 (6), p.3033-3041

1998

Volltextzugriff (PDF)

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells

The Journal of immunology (1950), 2003-02, Vol.170 (4), p.2004-2013

2003

Volltextzugriff (PDF)

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results

Human gene therapy, 2003-07, Vol.14 (11), p.1117-1123

2003

Volltextzugriff (PDF)

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells

Clinical cancer research, 2004-01, Vol.10 (2), p.668-680

2004

Volltextzugriff (PDF)

Medical progress : Hodgkin's disease

The New England journal of medicine, 1992-03, Vol.326 (10), p.678-687

1992

Volltextzugriff (PDF)

Alterations in T cell receptor and signal transduction molecules in melanoma patients

Clinical cancer research, 1995-11, Vol.1 (11), p.1327-1335

1995

Volltextzugriff (PDF)

Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L)

The Journal of immunology (1950), 1999-10, Vol.163 (8), p.4462-4472

1999

Volltextzugriff (PDF)

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

Journal of clinical oncology, 1992-02, Vol.10 (2), p.210-218

1992

Volltextzugriff (PDF)

Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy

The Journal of immunology (1950), 2001-06, Vol.166 (12), p.7370-7380

2001

Volltextzugriff (PDF)

Exacerbation of symptoms of autoimmune disease in patients receiving alpha‐interferon therapy

Cancer, 1990-05, Vol.65 (10), p.2237-2242

1990

Volltextzugriff (PDF)

Chemokine Receptor Desensitization in Tumor-Bearing Mice

Cellular immunology, 2001-02, Vol.207 (2), p.81-88

2001

Volltextzugriff (PDF)

Regression of a Mammary Adenocarcinoma in STAT6-/- Mice Is Dependent on the Presence of STAT6-Reactive T Cells

The Journal of immunology (1950), 2003-02, Vol.170 (4), p.2014-2021

2003

Volltextzugriff (PDF)

Tumour‐induced polarization of tumour vaccine‐draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

Immunology, 2003-03, Vol.108 (3), p.409-419

2003

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(113)

Sprache

Englisch
(113)

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(102)
Humans
(77)
Female
(61)
Oncology
(61)
Biological And Medical Sciences
(59)
Medical Sciences
(52)
Male
(43)
Middle Aged
(39)
Pharmacology. Drug Treatments
(38)
Adult
(34)
Antineoplastic Agents
(33)
Animals
(31)
Immunology
(31)
Aged
(29)
Mice
(28)
Immunotherapy
(23)
Mice, Inbred C57bl
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Cancer Vaccines - Immunology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Milestone for CAR T Cells

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC)

Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count

Development of antitumor immune responses in reconstituted lymphopenic hosts

Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing

Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution

Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses

Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy

Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells

Medical progress : Hodgkin's disease

Alterations in T cell receptor and signal transduction molecules in melanoma patients

Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L)

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy

Exacerbation of symptoms of autoimmune disease in patients receiving alpha‐interferon therapy

Chemokine Receptor Desensitization in Tumor-Bearing Mice

Regression of a Mammary Adenocarcinoma in STAT6-/- Mice Is Dependent on the Presence of STAT6-Reactive T Cells

Tumour‐induced polarization of tumour vaccine‐draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

Suchergebnisse filtern